Internal Report 17: “Musculoskeletal Adverse Events of Special Interest Afflicted 8.5% of Patients in Pfizer’s Post-Marketing Data Set, Including Four Children and One Infant. Women Affected at a Ratio of Almost 4:1 Over Men.”

The WarRoom/DailyClout Pfizer Documents Analysis Project Post-Marketing Group (Team 1)—Barbara Gehrett, MD; Joseph Gehrett, MD; Chris Flowers, MD; and Loree Britt—wrote a review of musculoskeletal adverse events of special interest (AESIs) found in Pfizer document 5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-FEB-2021 (a.k.a., “5.3.6 ”). This group of AESIs includes diagnoses of arthralgia (joint pain), arthritis (joint inflammation), arthritis/bacterial, chronic fatigue syndrome, polyarthritis (inflammation of multiple joints), post-viral fatigue syndrome, and rheumatoid arthritis (an autoimmune and inflammatory disease). It is important to note that the AESIs in the 5.3.6 document were reported to Pfizer for only a 90-day period starting on December 1, 2020, the date of the United Kingdom’s public rollout of Pfizer’s COVID-19 experimental mRNA “vaccine” product. Highlights of this report include:

• 3,600 cases of musculoskeletal AESIs were reported, which equates to 8.5% of the post-marketing data set of 42,086 cases/patients.
• The 3,600 patients reported 3,640 adverse events. 1,614 (44%) were classified as serious.
• The time from administration to adverse event ranged from less than 24 hours to 32 days. 50% of the events started within the first 24 hours after injection.
• Of the cases where gender was reported, 2,760 individuals were female, and 711 were male—an almost 4:1 ratio of female to male.
• Though mostly adults were affected with these AESIs, two adolescents, four children, and one infant also reported musculoskeletal AESIs during a time frame when Pfizer’s BNT162b2 mRNA COVID “vaccine” was not approved for use in individuals under 16 years of age.
• The most common adverse event was arthralgia/joint pain (3,525 or 97%), followed by 70 arthritis AESIs (2%), 26 rheumatoid arthritis AESIs (<1%) and 5 AESIs (<1%) polyarthritis.
• Outcome for 3,662 of the adverse events were: 1,801 (49%) resolved or resolving, 959 (26%) not resolved, 49 (1%) resolved with sequelae, and 853 (23%) were unknown.

Pfizer concluded, “This cumulative case review does not raise new safety issues. Surveillance will continue.” Please read the full report below.

[IMAGE 1 — ORIGINAL SOURCE PAGE 203; PLACE AFTER THE TEXT ABOVE]

[IMAGE 2 — ORIGINAL SOURCE PAGE 204; PLACE AFTER THE TEXT ABOVE]